The third dose of measles-containing vaccine induces robust immune responses against measles in young seronegative healthcare workers who had previous two-dose measles vaccination
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim, Yong Chan | - |
dc.contributor.author | Nam, Heejin | - |
dc.contributor.author | Choi, Jun Yong | - |
dc.contributor.author | Eui-Cheol Shin | - |
dc.contributor.author | Choi, Young Hwa | - |
dc.date.accessioned | 2023-10-18T22:01:08Z | - |
dc.date.available | 2023-10-18T22:01:08Z | - |
dc.date.created | 2023-08-28 | - |
dc.date.issued | 2023-10 | - |
dc.identifier.issn | 1876-0341 | - |
dc.identifier.uri | https://pr.ibs.re.kr/handle/8788114/13993 | - |
dc.description.abstract | Background: Despite the low measles antibody positivity rate among young healthcare workers (HCWs) who have previously received two doses of a measles-containing vaccine (MCV), whether an additional dose of MCV acts as a booster remains unknown. Thus, we aimed to evaluate the immune responses to a third dose of MCV in young HCWs. Methods: Hospital-wide measles seroprevalence was assessed using enzyme-linked immunosorbent assay (ELISA). The immunogenicity of a third dose of MCV was determined in young seronegative HCWs (born between 1986 and 1997) who had previously received a two-dose measles vaccination. Results: A total of 3033 (92.6%) HCWs had anti-measles immunoglobulin G. The lowest seropositivity rate was observed in HCWs aged 20–24 years (87.7%). In this group, HCWs who received a third dose of MCV had higher seropositivity than those who received a second dose (89.5% vs. 75.4%). A third dose of MCV was administered to 18 HCWs who did not have anti-measles IgG despite two doses. Neutralizing antibody titers increased significantly 4 weeks after the third vaccination. Although neutralizing antibody titers decreased 1 year post vaccination, 17 (94.4%) HCWs had medium (121–900 mIU/mL) or high (>900 mIU/mL) levels. Furthermore, the third dose of MCV increased the measles virus-specific T-cell effector function. Conclusions: The third dose of MCV induced a strong immune response against measles in young seronegative HCWs who had previously received a two-dose measles vaccination. © 2023 | - |
dc.language | 영어 | - |
dc.publisher | Elsevier BV | - |
dc.title | The third dose of measles-containing vaccine induces robust immune responses against measles in young seronegative healthcare workers who had previous two-dose measles vaccination | - |
dc.type | Article | - |
dc.type.rims | ART | - |
dc.identifier.wosid | 001099765600001 | - |
dc.identifier.scopusid | 2-s2.0-85168361854 | - |
dc.identifier.rimsid | 81551 | - |
dc.contributor.affiliatedAuthor | Eui-Cheol Shin | - |
dc.identifier.doi | 10.1016/j.jiph.2023.08.002 | - |
dc.identifier.bibliographicCitation | Journal of Infection and Public Health, v.16, no.10, pp.1643 - 1649 | - |
dc.relation.isPartOf | Journal of Infection and Public Health | - |
dc.citation.title | Journal of Infection and Public Health | - |
dc.citation.volume | 16 | - |
dc.citation.number | 10 | - |
dc.citation.startPage | 1643 | - |
dc.citation.endPage | 1649 | - |
dc.description.journalClass | 1 | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalWebOfScienceCategory | Public, Environmental & Occupational Health | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.subject.keywordPlus | RUBELLA VACCINE | - |
dc.subject.keywordPlus | MMR-VACCINE | - |
dc.subject.keywordPlus | IMMUNOGLOBULIN-G | - |
dc.subject.keywordPlus | ANTIBODY-LEVELS | - |
dc.subject.keywordPlus | MUMPS | - |
dc.subject.keywordPlus | SEROPREVALENCE | - |
dc.subject.keywordPlus | ELIMINATION | - |
dc.subject.keywordPlus | OUTBREAK | - |
dc.subject.keywordPlus | AVIDITY | - |
dc.subject.keywordPlus | KOREA | - |
dc.subject.keywordAuthor | Immunogenicity | - |
dc.subject.keywordAuthor | Measles | - |
dc.subject.keywordAuthor | Measles vaccine | - |
dc.subject.keywordAuthor | Safety | - |
dc.subject.keywordAuthor | Seroprevalence | - |